|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Dr. Jeffrey Nau MMS, Ph.D.||Pres, CEO & Director||962,85k||N/A||1975|
|Mr. Daniel Lochner M.B.A.||Chief Financial Officer||642k||N/A||1983|
|Mr. John Snisarenko M.B.A.||Chief Commercial Officer||634,95k||N/A||1963|
|Mr. George Donato M.B.A.||Sr. VP of CMC & Operations||N/A||N/A||N/A|
|Dr. Eric Carlson Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Arty Ahmed||VP of Investor relations||N/A||N/A||N/A|
|Mr. Barry Rosenfeld J.D.||Sr. VP & Gen. Counsel||N/A||N/A||N/A|
|Ms. Raegan A. McClain CCEP, J.D., L.L.M.||Chief Compliance & Privacy Officer||N/A||N/A||N/A|
|Ms. Karen Castillo-Paff||VP of Communications & PR||N/A||N/A||N/A|
|Mr. Dave Benadon||Chief HR Officer||N/A||N/A||N/A|
Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
El ISS Governance QualityScore de Oyster Point Pharma, Inc., a día 1 de mayo de 2022, es 9. Las puntuaciones base son Auditoría: 6; Tablero: 9; Derechos de los accionistas: 8; Compensación: 9.